{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:23:45Z","timestamp":1793413425808,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Precision medicine driven by clinical biomarkers is the state-of-art management approach for Parkinson's disease (PD). Whether pattern of striatal dopaminergic deficiency (demonstrated by single-photon emission CT (SPECT) scanning with\n                    <jats:sup>123<\/jats:sup>\n                    I-Ioflupane,\n                    <jats:italic>DaTSCAN<\/jats:italic>\n                    ) could be a biomarker predicting levodopa requirement in early PD is not known. Participants with early PD (disease duration (DD)\u2009\u2264\u20095 years, Hoehn and Yahr (H&amp;Y)\u2009\u2264\u20093) who underwent DaTSCAN as a part of clinical-diagnostic work up and were enrolled in the \u201cNon-motor Longitudinal International Study\u201d (UK National Institute for Health Research Clinical Research Network Number 10084) were included in this cross-sectional analysis. Specific DaTSCAN binding ratios were analyzed for each striatum, caudate nucleus and putamen and the z-scores were derived normalizing the images to age and gender-matched healthy controls from the European-Database-of-DaTSCAN-of-healthy-controls (ENC-DAT). Using linear regression analysis, we explored the impact of DaT-uptake z-scores for more severely affected putamen, caudate nucleus and striatum on the LEDD. Statistically significant predictors identified in the univariable analysis were included in the multivariable analysis with DD and H&amp;Y as additional independent variables. 43 PwP (30% female; age: 61.91\u2009\u00b1\u200911.45years; DD: 2(0\u20135) years; H&amp;Y: 2(1\u20133); LEDD: 424.27\u2009\u00b1\u2009342.62\u00a0mg) were assessed 19.12\u2009\u00b1\u200913.11 months following the DaTSCAN. In a multivariable linear regression analysis, when adjusted for DD and H&amp;Y, z-caudate nucleus (B=-134.073, 95% CI -262.715 - -5.431,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.042) and z-striatum (B=-162.137, 95% CI -306.306 - -17.967,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.028), were statistically significant predictors of LEDD, while z-putamen was not (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.086). In early PD, striatal DaT-uptake z-scores may serve as biomarkers that could aid the LEDD estimation and guide treatment decisions towards personalized care.\n                  <\/jats:p>","DOI":"10.1007\/s00702-025-02999-9","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T14:34:03Z","timestamp":1755354843000},"page":"137-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early parkinson\u2019s disease: levodopa requirements are associated with the striatal DaT-uptake"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8744-5058","authenticated-orcid":false,"given":"Katarina","family":"Rukavina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mulholland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Corcoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena Krbot","family":"Skoric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"1","key":"2999_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molbrainres.2004.09.028","volume":"134","author":"WL Au","year":"2005","unstructured":"Au WL, Adams JR, Troiano AR, Stoessl AJ (2005) Parkinson\u2019s disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res 134(1):24\u201333. https:\/\/doi.org\/10.1016\/j.molbrainres.2004.09.028","journal-title":"Brain Res Mol Brain Res"},{"issue":"1","key":"2999_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41531-021-00185-8","volume":"7","author":"D Bega","year":"2021","unstructured":"Bega D, Kuo PH, Chalkidou A, Grzeda MT, Macmillan T, Brand C, Antonini A (2021) Clinical utility of DaTscan in patients with suspected parkinsonian syndrome: a systematic review and meta-analysis. NPJ Parkinsons Dis 7(1):43. https:\/\/doi.org\/10.1038\/s41531-021-00185-8","journal-title":"NPJ Parkinsons Dis"},{"key":"2999_CR3","unstructured":"EMA DaTSCAN 74 MBq\/ml solution for injection. Retrieved from https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/datscan-epar-product-information_en.pdf"},{"key":"2999_CR4","doi-asserted-by":"publisher","first-page":"1064057","DOI":"10.3389\/fnagi.2022.1064057","volume":"14","author":"M Frasier","year":"2022","unstructured":"Frasier M, Fiske BK, Sherer TB (2022) Precision medicine for parkinson\u2019s disease: the subtyping challenge. Front Aging Neurosci 14:1064057. https:\/\/doi.org\/10.3389\/fnagi.2022.1064057","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"2999_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427\u2013442. https:\/\/doi.org\/10.1212\/wnl.17.5.427","journal-title":"Neurology"},{"issue":"3","key":"2999_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184. https:\/\/doi.org\/10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2999_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.parkreldis.2006.06.006","volume":"13","author":"C Jenkinson","year":"2007","unstructured":"Jenkinson C, Fitzpatrick R (2007) Cross-cultural evaluation of the short form 8-item parkinson\u2019s disease questionnaire (PDQ-8): results from america, canada, japan, Italy and Spain. Parkinsonism Relat Disord 13(1):22\u201328. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.06.006","journal-title":"Parkinsonism Relat Disord"},{"key":"2999_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-022-02571-9","author":"SH Jeong","year":"2022","unstructured":"Jeong SH, Park CW, Lee HS, Kim YJ, Yun M, Lee PH, Chung SJ (2022) Patterns of striatal dopamine depletion and motor deficits in de Novo parkinson\u2019s disease. J Neural Transm (Vienna). https:\/\/doi.org\/10.1007\/s00702-022-02571-9","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"2999_CR10","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.parkreldis.2015.10.017","volume":"21","author":"SY Liu","year":"2015","unstructured":"Liu SY, Wu JJ, Zhao J, Huang SF, Wang YX, Ge JJ, Wang J (2015) Onset-related subtypes of parkinson\u2019s disease differ in the patterns of striatal dopaminergic dysfunction: A positron emission tomography study. Parkinsonism Relat Disord 21(12):1448\u20131453. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.10.017","journal-title":"Parkinsonism Relat Disord"},{"key":"2999_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.parkreldis.2020.02.001","volume":"72","author":"R Liu","year":"2020","unstructured":"Liu R, Umbach DM, Troster AI, Huang X, Chen H (2020) Non-motor symptoms and striatal dopamine transporter binding in early parkinson\u2019s disease. Parkinsonism Relat Disord 72:23\u201330. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.02.001","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"2999_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jclinepi.2004.09.014","volume":"58","author":"P Martinez-Martin","year":"2005","unstructured":"Martinez-Martin P, Benito-Leon J, Burguera JA, Castro A, Linazasoro G, Martinez-Castrillo JC, Frades B (2005) The SCOPA-Motor scale for assessment of parkinson\u2019s disease is a consistent and valid measure. J Clin Epidemiol 58(7):674\u2013679. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.09.014","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2999_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group NV (2011) The impact of non-motor symptoms on health-related quality of life of patients with parkinson\u2019s disease. Mov Disord 26(3):399\u2013406. https:\/\/doi.org\/10.1002\/mds.23462","journal-title":"Mov Disord"},{"key":"2999_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2025.100331","author":"AH Najmi","year":"2025","unstructured":"Najmi AH, Ariaei A, Khezri M, Noroozi M, Bafrani MA, Gheysari A (2025) Longitudinal Assessment of Parkinson\u2019s Motor Symptoms and Dopaminergic Dysfunction Patterns Using DaTSCAN. Clin Park Relat Disord 12:100331. https:\/\/doi.org\/10.1016\/j.prdoa.2025.100331. Parkinson\u2019s Progression Markers, I"},{"issue":"10","key":"2999_CR14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/jnnp-2018-320157","volume":"90","author":"J Pasquini","year":"2019","unstructured":"Pasquini J, Durcan R, Wiblin L, Gersel Stokholm M, Rochester L, Brooks DJ, Pavese N (2019) Clinical implications of early caudate dysfunction in parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 90(10):1098\u20131104. https:\/\/doi.org\/10.1136\/jnnp-2018-320157","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 7","key":"2999_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/mds.10579","volume":"18","author":"W Pirker","year":"2003","unstructured":"Pirker W (2003) Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 18(Suppl 7):43\u201351. https:\/\/doi.org\/10.1002\/mds.10579","journal-title":"Mov Disord"},{"issue":"12","key":"2999_CR16","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Deuschl G (2015) MDS clinical diagnostic criteria for parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"issue":"6","key":"2999_CR17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, Loschmann PA, Monoranu CM (2025) Levodopa treatment: impacts and mechanisms throughout parkinson\u2019s disease progression. J Neural Transm (Vienna) 132(6):743\u2013779. https:\/\/doi.org\/10.1007\/s00702-025-02893-4","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"2999_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14737175.2021.1883428","volume":"21","author":"K Rukavina","year":"2021","unstructured":"Rukavina K, Batzu L, Boogers A, Abundes-Corona A, Bruno V, Chaudhuri KR (2021) Non-motor complications in late stage parkinson\u2019s disease: recognition, management and unmet needs. Expert Rev Neurother 21(3):335\u2013352. https:\/\/doi.org\/10.1080\/14737175.2021.1883428","journal-title":"Expert Rev Neurother"},{"key":"2999_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.2172","author":"K Rukavina","year":"2023","unstructured":"Rukavina K, Mulholland N, Corcoran B, Skoric MK, Staunton J, Rota S, Chaudhuri KR (2023) Musculoskeletal pain in parkinson\u2019s disease: association with dopaminergic deficiency in the caudate nucleus. Eur J Pain. https:\/\/doi.org\/10.1002\/ejp.2172","journal-title":"Eur J Pain"},{"issue":"3","key":"2999_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/mdc3.12921","volume":"7","author":"S Schade","year":"2020","unstructured":"Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including Opicapone and Safinamide. Mov Disord Clin Pract 7(3):343\u2013345. https:\/\/doi.org\/10.1002\/mdc3.12921","journal-title":"Mov Disord Clin Pract"},{"issue":"12","key":"2999_CR21","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1007\/s00259-005-1922-9","volume":"32","author":"O Schillaci","year":"2005","unstructured":"Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, Stanzione P (2005) The effect of Levodopa therapy on dopamine transporter SPECT imaging with(123)I-FP-CIT in patients with parkinson\u2019s disease. Eur J Nucl Med Mol Imaging 32(12):1452\u20131456. https:\/\/doi.org\/10.1007\/s00259-005-1922-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2999_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/mds.27027","volume":"32","author":"N Titova","year":"2017","unstructured":"Titova N, Chaudhuri KR (2017) Personalized medicine in parkinson\u2019s disease: time to be precise. Mov Disord 32(8):1147\u20131154. https:\/\/doi.org\/10.1002\/mds.27027","journal-title":"Mov Disord"},{"issue":"8","key":"2999_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00702-016-1667-6","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova N, Padmakumar C, Lewis SJG, Chaudhuri KR (2017) Parkinson\u2019s: a syndrome rather than a disease? J Neural Transm (Vienna) 124(8):907\u2013914. https:\/\/doi.org\/10.1007\/s00702-016-1667-6","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"2999_CR24","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1007\/s00415-023-11563-y","volume":"270","author":"K Tsang","year":"2023","unstructured":"Tsang K, Walker R (2023) Dopamine transporter single photon emission computed tomography (DaT-SPECT) use in the diagnosis and clinical management of parkinsonism: an 8-year retrospective study. J Neurol 270(5):2550\u20132558. https:\/\/doi.org\/10.1007\/s00415-023-11563-y","journal-title":"J Neurol"},{"key":"2999_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41531-019-0094-4","volume":"5","author":"DJ van Wamelen","year":"2019","unstructured":"van Wamelen DJ, Hota S, Podlewska A, Leta V, Trivedi D, Rizos A, Chaudhuri KR (2019) Non-motor correlates of wrist-worn wearable sensor use in parkinson\u2019s disease: an exploratory analysis. NPJ Parkinsons Dis 5:22. https:\/\/doi.org\/10.1038\/s41531-019-0094-4","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"2999_CR26","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.1038\/s41598-021-88651-4","volume":"11","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen DJ, Sauerbier A, Leta V, Rodriguez-Blazquez C, Falup-Pecurariu C, Rodriguez-Violante M, Chaudhuri KR (2021) Cross-sectional analysis of the parkinson\u2019s disease Non-motor international longitudinal study baseline non-motor characteristics, geographical distribution and impact on quality of life. Sci Rep 11(1):9611. https:\/\/doi.org\/10.1038\/s41598-021-88651-4","journal-title":"Sci Rep"},{"issue":"2","key":"2999_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00259-012-2276-8","volume":"40","author":"A Varrone","year":"2013","unstructured":"Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, Tatsch K (2013) European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 40(2):213\u2013227. https:\/\/doi.org\/10.1007\/s00259-012-2276-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2999_CR28","unstructured":"Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, Katz IR (2005) Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson\u2019s disease. J Nucl Med, 46(2):227\u2013232. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15695780"},{"issue":"2","key":"2999_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1109\/TMI.2020.3031478","volume":"40","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Tinaz S, Tagare HD (2021) Robust bayesian analysis of Early-Stage parkinson\u2019s disease progression using DaTscan images. IEEE Trans Med Imaging 40(2):549\u2013561. https:\/\/doi.org\/10.1109\/TMI.2020.3031478","journal-title":"IEEE Trans Med Imaging"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02999-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-02999-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02999-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:33:47Z","timestamp":1769092427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-02999-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2999"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-02999-9","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.prdoa.2025.100331","asserted-by":"subject"}]},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"23 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}